GlassScriptPhysician profile
Si Tien Lam
NPI 1992192744
$4,740.41
in general payments reported to CMS, 2019-2025
29 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $276 · 2021: $316 · 2022: $237 · 2023: $460 · 2024: $2,515 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,973 · Food and Beverage: $1,641 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,972.95 |
| Food and Beverage | $1,641.09 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,972.95 | 2024 | |
| Novo Nordisk INC | $801.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $309.85 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $186.86 | 2019-2025 | |
| Vericel Corporation | $144.83 | 2025 | Maci |
| Bayer Healthcare Pharmaceuticals INC. | $119.97 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.57 | 2022-2025 | Jardiance |
| Amarin Pharma, INC. | $101.47 | 2019-2021 | |
| Esperion Therapeutics, INC. | $98.28 | 2023-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $92.54 | 2022-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.99 | 2021-2024 | Cycloset |
| Glaxosmithkline, LLC. | $72.09 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $70.24 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $69.87 | 2025 | Aplenzin |
| Dynavax Technologies Corporation | $61.46 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.73 | 2019-2021 | |
| Lundbeck LLC | $55.95 | 2021-2025 | Rexulti |
| Sanofi Pasteur INC. | $52.92 | 2023-2025 | |
| Abbvie INC. | $47.49 | 2023 | |
| Exact Sciences Corporation | $40.04 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $33.91 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $30.61 | 2025 | |
| Alexion Pharmaceuticals, INC. | $27.80 | 2025 | Ultomiris |
| Kowa Pharmaceuticals America, INC. | $25.75 | 2020-2021 | |
| Dexcom, INC. | $23.92 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $17.96 | 2023 | |
| Axsome Therapeutics, INC. | $17.09 | 2025 | Auvelity |
| Eisai INC. | $15.40 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.73 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Si Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.